Janux Therapeutics, Inc. (JANX)
18.14
-0.64
(-3.41%)
USD |
NASDAQ |
Aug 28, 13:59
Janux Therapeutics Debt to Equity Ratio : 0.0226 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0226 |
| March 31, 2026 | 0.0229 |
| December 31, 2025 | 0.0231 |
| September 30, 2025 | 0.0232 |
| June 30, 2025 | 0.0224 |
| March 31, 2025 | 0.0223 |
| December 31, 2024 | 0.0225 |
| September 30, 2024 | 0.0357 |
| June 30, 2024 | 0.0362 |
| March 31, 2024 | 0.0369 |
| December 31, 2023 | 0.0713 |
| September 30, 2023 | 0.0713 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.0842 |
| March 31, 2023 | 0.0821 |
| December 31, 2022 | 0.0789 |
| September 30, 2022 | 0.0727 |
| June 30, 2022 | 0.0679 |
| March 31, 2022 | 0.0004 |
| December 31, 2021 | 0.0005 |
| September 30, 2021 | 0.0006 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| MacroGenics, Inc. | 4.624 |
| Agenus, Inc. | -1.458 |
| Amgen, Inc. | 4.903 |
| Anika Therapeutics, Inc. | 0.1839 |
| BioCryst Pharmaceuticals, Inc. | -1.842 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.008B |
| Total Liabilities (Quarterly) | 79.67M |
| Shareholders Equity (Quarterly) | 927.98M |
| Current Ratio | 16.35 |
| Net Debt Paydown Yield | 0.03% |